Actinium Pharmaceuticals Inc reports a Return on Equity (ROE) of -1,018.71%.

What is ATNM's dividend yield?

Actinium Pharmaceuticals Inc offers a dividend yield of 0.00%.

What is ATNM's Quality Score?

Our AI rates ATNM's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ATNM?

Our AI Timing Score for ATNM is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ATNM belong to?

Actinium Pharmaceuticals Inc is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange

Actinium Pharmaceuticals Inc (ATNM) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

ATNM AI Analysis Summary

Our AI summary for ATNM: Actinium Pharmaceuticals Inc (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at ROE of -1,018.71%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ATNM

Actinium Pharmaceuticals Inc

US:NYSE MKT STOCK Healthcare >> Biotechnology News 67

USD 0.75

-0.06 (-7.57%) Day Change

Watchlist Portfolio Compare Chart

0.32

D/E

-1,018.7%

ROE

-51.7%

ROA

0.00%

Div Yield

ACTINIUM PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NYSE MKT

Compare Watchlist Myport

USD 0.75 Price -0.06 (-7.57%) Day Change	NEWS SCORE: 67

ATNM, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	67
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.75
PBV / Sector	11.03 / 44,105.10
Earning Per Share	-0.69

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	0.08 M GREAT
Average 1W Daily Value	0.11 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-26,078.89 / 97.23
NPM Average (%) / Sector	-31,801.45 / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-51.66 / 185,260.64
ROA Average (%) / Sector	-51.14 / 36,684.64
ROA Change Average (%) / Sector	25.20 / 422,221.42 GREAT
ROE (%) / Sector	-1,018.71 / 243,761.81
ROE Average (%) / Sector	-350.37 / 48,758.38
ROE Change Average (%) / Sector	140.81 / 424,967.86 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 07:59:39
Symbol	ATNM
Name	ACTINIUM PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NYSE MKT
Listed Shares	31.37 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	25.41 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 100 Park Avenue, New York, NY, United States, 10017

Phone: 646 677 3870

Website: https://www.actiniumpharma.com

Sector: Healthcare >> Biotechnology

Description: Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.